Globeflex Capital L P decreased its stake in shares of Alkermes PLC (NASDAQ:ALKS) by 23.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,670 shares of the company’s stock after selling 6,810 shares during the period. Globeflex Capital L P’s holdings in Alkermes PLC were worth $1,268,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Fiera Capital Corp raised its position in shares of Alkermes PLC by 2.1% in the fourth quarter. Fiera Capital Corp now owns 5,516 shares of the company’s stock valued at $307,000 after buying an additional 116 shares during the period. A.R.T. Advisors LLC acquired a new position in shares of Alkermes PLC during the fourth quarter valued at about $4,162,000. Greenwood Capital Associates LLC acquired a new position in shares of Alkermes PLC during the fourth quarter valued at about $202,000. Allianz Asset Management AG raised its position in shares of Alkermes PLC by 81.3% in the fourth quarter. Allianz Asset Management AG now owns 166,631 shares of the company’s stock valued at $9,261,000 after buying an additional 74,723 shares during the period. Finally, Credit Agricole S A raised its position in shares of Alkermes PLC by 1,352.5% in the fourth quarter. Credit Agricole S A now owns 256,799 shares of the company’s stock valued at $14,272,000 after buying an additional 239,119 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.
Alkermes PLC (NASDAQ:ALKS) traded down 0.57% during mid-day trading on Tuesday, reaching $57.18. The company’s stock had a trading volume of 1,222,777 shares. Alkermes PLC has a 52 week low of $39.65 and a 52 week high of $63.40. The firm’s market capitalization is $8.76 billion. The company’s 50-day moving average price is $58.60 and its 200 day moving average price is $57.18.
Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings results on Thursday, April 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.07. Alkermes PLC had a negative return on equity of 9.76% and a negative net margin of 25.61%. The firm had revenue of $191.80 million for the quarter, compared to analyst estimates of $195.79 million. During the same quarter last year, the firm earned ($0.16) earnings per share. The company’s revenue was up 22.3% compared to the same quarter last year. On average, equities analysts forecast that Alkermes PLC will post ($0.04) earnings per share for the current fiscal year.
Several brokerages have issued reports on ALKS. Cowen and Company restated a “positive” rating and set a $65.00 target price on shares of Alkermes PLC in a research report on Tuesday, March 21st. ValuEngine upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Leerink Swann lowered Alkermes PLC from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $68.00 to $61.00 in a report on Tuesday, June 13th. Credit Suisse Group reiterated a “buy” rating and issued a $70.00 price target on shares of Alkermes PLC in a report on Wednesday, June 7th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $70.00 price target on shares of Alkermes PLC in a report on Monday, April 3rd. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Alkermes PLC has a consensus rating of “Hold” and a consensus target price of $63.10.
In other news, insider Shane Cooke sold 6,030 shares of the business’s stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $60.01, for a total transaction of $361,860.30. Following the transaction, the insider now directly owns 74,948 shares in the company, valued at $4,497,629.48. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard F. Pops sold 25,000 shares of the company’s stock in a transaction dated Wednesday, May 10th. The stock was sold at an average price of $57.29, for a total transaction of $1,432,250.00. Following the transaction, the director now owns 655,406 shares in the company, valued at $37,548,209.74. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 172,600 shares of company stock worth $10,004,235. Company insiders own 5.34% of the company’s stock.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.